A district court ruled that the HHS does have the power to review drug manufacturers’ plans to pay hospitals rebates instead of upfront discounts on 340B medications. But it left the door open to the controversial reforms.
A district court ruled that the HHS does have the power to review drug manufacturers’ plans to pay hospitals rebates instead of upfront discounts on 340B medications. But it left the door open to the controversial reforms.